Recurrent Calcium Stones: Thiazide Prevention After the Evidence Shifted
A recurrent stone former with hypercalciuria and low urinary citrate, and a decades-old thiazide recommendation that a large recent trial just failed to reproduce.
Ray O., a 39-year-old long-haul truck driver, has passed three stones in the last three years and was in the emergency department again last week for a fourth — each one, he says, has landed somewhere between deliveries, on routes where the nearest exit with a working restroom might be forty minutes away. The first two episodes he managed at truck stops without ever seeing a doctor, assuming it was something he'd eaten; only the third, which put him in an emergency department two states from home, got formally diagnosed as a kidney stone at all. He'd never mentioned any of it, or his hydration habits, to a doctor before this admission, but he's been deliberately cutting back on water during long stretches of driving for years, a habit that started as a practical accommodation to his route and never got revisited once it became routine.
His first complete 24-hour urine collection, obtained after this fourth episode, shows hypercalciuria at 320 mg/day and low urinary citrate at 280 mg/day — two independent risk factors, either of which could be driving recurrent calcium oxalate stone formation on its own, compounded by the concentrated, infrequent urine his driving habits produce. For decades, guideline-recommended first-line prevention for hypercalciuric calcium stone formers has been a thiazide diuretic, on evidence going back to Borghi-era trials from the 1990s, which largely tested indapamide, a thiazide-like agent, not hydrochlorothiazide itself — a distinction that matters directly in a case turning on which thiazide to use. The NOSTONE trial, published in 2023, tested that recommendation directly: hydrochlorothiazide at three different doses against placebo in over 400 recurrent calcium stone formers followed for three years, making it the largest and longest randomized trial ever run on the question, and it found no significant dose-dependent reduction in stone recurrence at any dose tested — a result that directly challenges decades of guideline language for the specific drug and doses it studied, in a patient who is the textbook profile that language was written for. The guidelines Ray's own workup was measured against haven't caught up to that finding yet, which leaves the group deciding tonight with better evidence than the recommendation they're used to citing, not less.
At the stone-prevention clinic visit
I'd still reach for a thiazide here — just chlorthalidone rather than hydrochlorothiazide. NOSTONE tested HCTZ at three doses and found no benefit, but chlorthalidone is longer-acting and more potent on distal tubular calcium reabsorption; it hasn't been tested head-to-head against placebo the way HCTZ just was. Older cohort data still supports the thiazide class broadly, and I don't think one negative trial for one drug settles the whole class.
You're right that NOSTONE tested a different drug than the one you're proposing — I can't claim equivalent proof against chlorthalidone specifically. But NOSTONE is also the best-designed, best-powered trial anyone has ever run on this exact question, and it found nothing at any dose. Reaching for an unproven alternative in the same class, with real side effects of its own, isn't obviously better than starting with the drug that has the clearest mechanistic match to his actual abnormality: potassium citrate, for his documented low urinary citrate.
Absence of proof for chlorthalidone isn't proof of absence of benefit — but I agree it isn't a reason to start it today ahead of an intervention we already know targets his specific lab abnormality.
Before either thiazide question gets settled, I'd want his hydration addressed directly. He's been deliberately restricting fluids for years because of his route — that alone concentrates his urine and plausibly drives a meaningful share of both the hypercalciuria and the low citrate. No drug fixes that if the behavior continues. I'd start potassium citrate now for the documented abnormality, address hydration concretely for his specific job, and repeat the 24-hour urine before deciding whether either thiazide is still needed.
Agreed: start potassium citrate, address hydration concretely around his driving schedule, and repeat a full 24-hour urine collection in three months to see whether hypercalciuria persists once citrate and fluid intake are both addressed.
Not agreed: whether chlorthalidone should be added now alongside citrate rather than held. The group left this for the repeat urine results rather than deciding it today.